Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease. 1996

J T Klein, and L Davis, and G E Olsen, and G S Wong, and F P Huger, and C P Smith, and W W Petko, and M Cornfeldt, and J C Wilker, and R D Blitzer, and E Landau, and V Haroutunian, and L L Martin, and R C Effland
Hoechst-Roussel Pharmaceuticals Inc., Somerville, New Jersey 08876, USA.

A series of novel N-(4-pyridinyl)-1H-indol-1-amines and other heteroaryl analogs was synthesized and evaluated in tests to determine potential utility for the treatment of Alzheimer's disease. From these compounds, N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine, 4c) was selected for clinical development based on in-depth biological evaluation. In addition to cholinomimetic properties based initially on in vitro inhibition of [3H]quinuclidinyl benzilate binding, in vivo reversal of scopolamine-induced behavioral deficits, and subsequently on other results, 4c also displayed enhancement of adrenergic mechanisms as evidenced in vitro by inhibition of [3H] clonidine binding and synaptosomal biogenic amine uptake, and in vivo by reversal of tetrabenazine-induced ptosis. The synthesis, structure-activity relationships for this series, and the biological profile of 4c are reported.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D010276 Parasympatholytics Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. Antispasmodic,Antispasmodic Agent,Antispasmodic Drug,Antispasmodics,Parasympathetic-Blocking Agent,Parasympathetic-Blocking Agents,Parasympatholytic,Parasympatholytic Agent,Parasympatholytic Drug,Spasmolytic,Spasmolytics,Antispasmodic Agents,Antispasmodic Drugs,Antispasmodic Effect,Antispasmodic Effects,Parasympatholytic Agents,Parasympatholytic Drugs,Parasympatholytic Effect,Parasympatholytic Effects,Agent, Antispasmodic,Agent, Parasympathetic-Blocking,Agent, Parasympatholytic,Agents, Antispasmodic,Agents, Parasympathetic-Blocking,Agents, Parasympatholytic,Drug, Antispasmodic,Drug, Parasympatholytic,Drugs, Antispasmodic,Drugs, Parasympatholytic,Effect, Antispasmodic,Effect, Parasympatholytic,Effects, Antispasmodic,Effects, Parasympatholytic,Parasympathetic Blocking Agent,Parasympathetic Blocking Agents
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001679 Biogenic Amines A group of naturally occurring amines derived by enzymatic decarboxylation of the natural amino acids. Many have powerful physiological effects (e.g., histamine, serotonin, epinephrine, tyramine). Those derived from aromatic amino acids, and also their synthetic analogs (e.g., amphetamine), are of use in pharmacology. Amines, Biogenic,Biogenic Amine,Amine, Biogenic
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

J T Klein, and L Davis, and G E Olsen, and G S Wong, and F P Huger, and C P Smith, and W W Petko, and M Cornfeldt, and J C Wilker, and R D Blitzer, and E Landau, and V Haroutunian, and L L Martin, and R C Effland
September 2020, Molecules (Basel, Switzerland),
J T Klein, and L Davis, and G E Olsen, and G S Wong, and F P Huger, and C P Smith, and W W Petko, and M Cornfeldt, and J C Wilker, and R D Blitzer, and E Landau, and V Haroutunian, and L L Martin, and R C Effland
September 2012, Bioorganic & medicinal chemistry letters,
J T Klein, and L Davis, and G E Olsen, and G S Wong, and F P Huger, and C P Smith, and W W Petko, and M Cornfeldt, and J C Wilker, and R D Blitzer, and E Landau, and V Haroutunian, and L L Martin, and R C Effland
September 2009, Bioorganic & medicinal chemistry,
J T Klein, and L Davis, and G E Olsen, and G S Wong, and F P Huger, and C P Smith, and W W Petko, and M Cornfeldt, and J C Wilker, and R D Blitzer, and E Landau, and V Haroutunian, and L L Martin, and R C Effland
May 2007, European journal of medicinal chemistry,
J T Klein, and L Davis, and G E Olsen, and G S Wong, and F P Huger, and C P Smith, and W W Petko, and M Cornfeldt, and J C Wilker, and R D Blitzer, and E Landau, and V Haroutunian, and L L Martin, and R C Effland
December 1989, Die Pharmazie,
J T Klein, and L Davis, and G E Olsen, and G S Wong, and F P Huger, and C P Smith, and W W Petko, and M Cornfeldt, and J C Wilker, and R D Blitzer, and E Landau, and V Haroutunian, and L L Martin, and R C Effland
October 2013, Acta crystallographica. Section E, Structure reports online,
J T Klein, and L Davis, and G E Olsen, and G S Wong, and F P Huger, and C P Smith, and W W Petko, and M Cornfeldt, and J C Wilker, and R D Blitzer, and E Landau, and V Haroutunian, and L L Martin, and R C Effland
December 2020, Journal of enzyme inhibition and medicinal chemistry,
J T Klein, and L Davis, and G E Olsen, and G S Wong, and F P Huger, and C P Smith, and W W Petko, and M Cornfeldt, and J C Wilker, and R D Blitzer, and E Landau, and V Haroutunian, and L L Martin, and R C Effland
January 2009, Bioorganic & medicinal chemistry letters,
J T Klein, and L Davis, and G E Olsen, and G S Wong, and F P Huger, and C P Smith, and W W Petko, and M Cornfeldt, and J C Wilker, and R D Blitzer, and E Landau, and V Haroutunian, and L L Martin, and R C Effland
January 2015, European journal of medicinal chemistry,
J T Klein, and L Davis, and G E Olsen, and G S Wong, and F P Huger, and C P Smith, and W W Petko, and M Cornfeldt, and J C Wilker, and R D Blitzer, and E Landau, and V Haroutunian, and L L Martin, and R C Effland
July 2009, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!